Biologic agents as adjunctive therapy for prostate cancer: A rationale for use with androgen deprivation

Eric C. Nelson, Angelo J. Cambio, Joy C. Yang, Primo N Lara, Christopher P Evans

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The prevalence of prostate cancer emphasizes the need for improved therapeutic options, particularly for metastatic disease. Current treatment includes medical or surgical castration, which initially induces apoptosis of prostate cancer cells, but ultimately an androgen-independent subpopulation emerges. In addition to a transient therapeutic effect, androgen-deprivation therapy (ADT) can initiate biochemical events that may contribute to the development of and progression to an androgen-independent state. This transition involves multiple signal transduction pathways that are accompanied by many biochemical changes resulting from ADT. These molecular events themselves are therapeutic targets and serve as a rationale for adjunctive treatment at the time of ADT.

Original languageEnglish (US)
Pages (from-to)82-94
Number of pages13
JournalNature Clinical Practice Urology
Volume4
Issue number2
DOIs
StatePublished - Feb 2007

Fingerprint

Biological Factors
Androgens
Prostatic Neoplasms
Therapeutics
Castration
Therapeutic Uses
Signal Transduction
Apoptosis

ASJC Scopus subject areas

  • Urology
  • Nephrology

Cite this

Biologic agents as adjunctive therapy for prostate cancer : A rationale for use with androgen deprivation. / Nelson, Eric C.; Cambio, Angelo J.; Yang, Joy C.; Lara, Primo N; Evans, Christopher P.

In: Nature Clinical Practice Urology, Vol. 4, No. 2, 02.2007, p. 82-94.

Research output: Contribution to journalArticle

@article{2845d31d07d845c5bab746fdad04351a,
title = "Biologic agents as adjunctive therapy for prostate cancer: A rationale for use with androgen deprivation",
abstract = "The prevalence of prostate cancer emphasizes the need for improved therapeutic options, particularly for metastatic disease. Current treatment includes medical or surgical castration, which initially induces apoptosis of prostate cancer cells, but ultimately an androgen-independent subpopulation emerges. In addition to a transient therapeutic effect, androgen-deprivation therapy (ADT) can initiate biochemical events that may contribute to the development of and progression to an androgen-independent state. This transition involves multiple signal transduction pathways that are accompanied by many biochemical changes resulting from ADT. These molecular events themselves are therapeutic targets and serve as a rationale for adjunctive treatment at the time of ADT.",
author = "Nelson, {Eric C.} and Cambio, {Angelo J.} and Yang, {Joy C.} and Lara, {Primo N} and Evans, {Christopher P}",
year = "2007",
month = "2",
doi = "10.1038/ncpuro0700",
language = "English (US)",
volume = "4",
pages = "82--94",
journal = "Nature Reviews Urology",
issn = "1759-4812",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Biologic agents as adjunctive therapy for prostate cancer

T2 - A rationale for use with androgen deprivation

AU - Nelson, Eric C.

AU - Cambio, Angelo J.

AU - Yang, Joy C.

AU - Lara, Primo N

AU - Evans, Christopher P

PY - 2007/2

Y1 - 2007/2

N2 - The prevalence of prostate cancer emphasizes the need for improved therapeutic options, particularly for metastatic disease. Current treatment includes medical or surgical castration, which initially induces apoptosis of prostate cancer cells, but ultimately an androgen-independent subpopulation emerges. In addition to a transient therapeutic effect, androgen-deprivation therapy (ADT) can initiate biochemical events that may contribute to the development of and progression to an androgen-independent state. This transition involves multiple signal transduction pathways that are accompanied by many biochemical changes resulting from ADT. These molecular events themselves are therapeutic targets and serve as a rationale for adjunctive treatment at the time of ADT.

AB - The prevalence of prostate cancer emphasizes the need for improved therapeutic options, particularly for metastatic disease. Current treatment includes medical or surgical castration, which initially induces apoptosis of prostate cancer cells, but ultimately an androgen-independent subpopulation emerges. In addition to a transient therapeutic effect, androgen-deprivation therapy (ADT) can initiate biochemical events that may contribute to the development of and progression to an androgen-independent state. This transition involves multiple signal transduction pathways that are accompanied by many biochemical changes resulting from ADT. These molecular events themselves are therapeutic targets and serve as a rationale for adjunctive treatment at the time of ADT.

UR - http://www.scopus.com/inward/record.url?scp=33846958453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846958453&partnerID=8YFLogxK

U2 - 10.1038/ncpuro0700

DO - 10.1038/ncpuro0700

M3 - Article

C2 - 17287869

AN - SCOPUS:33846958453

VL - 4

SP - 82

EP - 94

JO - Nature Reviews Urology

JF - Nature Reviews Urology

SN - 1759-4812

IS - 2

ER -